This site is intended for U.S. healthcare professionals.

Deeper Than Diagnosis logo Deeper Than Diagnosis logo

IN MYELODYSPLASTIC SYNDROMES (MDS)

GO DEEPER THAN DIAGNOSIS

Explore why

Patients with MDS benefit from repeat molecular testing

Test early. Test again. Take action.

Improve prognostic assessment for MDS with the inclusion of molecular test results and identification of key mutations, such as mIDH1, in your risk stratification.1,2

Adoption of IPSS-M can improve prognostic accuracy for patients with MDS1
Assess MDS risk
~30% of patients with MDS eventually progress to AML3
Identify at-risk patients
Resources about MDS and AML to help support you and your practice
Dig deeper

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) notes that as the population ages, the incidence of AML along with MDS is rising.4

Diagnosing MDS
Diagnosing AML
 
Sign up now to receive updates about MDS and AML from Servier Pharmaceuticals.
*Indicates required field

By clicking submit, you opt in to receive email updates from Servier Pharmaceuticals. You may unsubscribe at any time. Data may be used in accordance with the Privacy Policy.

AML, acute myeloid leukemia; IDH1, isocitrate dehydrogenase-1; IPSS-M, International Prognostic Scoring System-Molecular; mIDH1, mutated IDH1; NCCN, National Comprehensive Cancer Network® (NCCN®).

References: 1. Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1(7). doi:10.1056/EVIDoa2200008 2. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95(10):1668-1674. doi:10.3324/haematol.2010.025494 3. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76-89. doi:10.1002/ajh.24253 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.